Intas Pharmaceuticals
PrivateLast Round
Secondary
Oct 11, 2022
Est. Valuation
$8.5B
Total Funding Raised
$57.1M
Company Overview
Intas Pharmaceuticals is a pharmaceutical company that develops, manufactures, and commercializes generic drugs, biosimilars, and specialty pharmaceutical products for global markets.
Sector
Healthcare & Life Sciences
Verticals
Pharma Supply Chain, Biotechnology, Clinical Trials, Drug Discovery, Quality Management
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Intas Pharmaceuticals Comparables
Compare Intas Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alkem Laboratories | 85% | |
| Aurobindo Pharma Limited | 85% | |
| Emcure Pharmaceuticals Ltd | 85% |
For institutional investors. Book with your work email.
Intas Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Secondary | Oct 11, 2022 | ||||
| Secondary | Jun 2, 2020 | ||||
| Secondary | Apr 3, 2017 | ||||
| Secondary | Nov 10, 2014 | ||||
| Private Equity | Apr 26, 2012 | ||||
Secondary | Jan 6, 2006 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Intas Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ICICI Venture | Secondary |
| ChrysCapital | Secondary, Private Equity |
| Temasek | Secondary |
| Abu Dhabi Investment Authority | Secondary |
| Capital Group | Secondary |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2022
$260M round led by Abu Dhabi Investment Authority
- Jun 2, 2020
$132M round led by ChrysCapital
For institutional investors. Book with your work email.
Intas Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Appears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Intas Pharmaceuticals's valuation, stock price, and market status.
Is Intas Pharmaceuticals a public or private company?
Intas Pharmaceuticals is a private company.
What is the current stock price of Intas Pharmaceuticals?
Intas Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Intas Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Intas Pharmaceuticals worth (valuation)?
Intas Pharmaceuticals's valuation is estimated at $8.5B based on funding round data.
Can I buy Intas Pharmaceuticals stock?
Intas Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Intas Pharmaceuticals's last funding round?
Intas Pharmaceuticals's most recent funding round was Secondary on October 11, 2022.
Who are the main investors in Intas Pharmaceuticals?
Key investors in Intas Pharmaceuticals include ChrysCapital, Temasek, Abu Dhabi Investment Authority.
Will Intas Pharmaceuticals IPO soon?
No public IPO plans have been announced for Intas Pharmaceuticals.
How can I track Intas Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Intas Pharmaceuticals's shares on secondary markets.